NEW YORK (GenomeWeb News) – Mitomics today announced a deal with Laboratory Corporation of America to offer Mitomics' molecular prostate cancer test.
Under the terms of the deal, urologists will be able to order Mitomics' Prostate Core Mitomic Test through Dianon Systems, LabCorp's specialized laboratory subsidiary focused on anatomic pathology. The test will be performed at Mitomics' CLIA laboratory in Aurora, Colo.
"This agreement supports our commercial strategy to provide broad access to [the test] and further validates the strong demand from physicians to improve the diagnosis of prostate cancer for patients," Robert Poulter, president and CEO of Thunder Bay, Ontario-based Mitomics, said in a statement.
The mitochondrial DNA-based test uses previously obtained prostate biopsy tissue to determine the presence of malignant cells "via a cancerization field effect" by detecting molecular changes in tissue that appears normal.
Financial terms of the deal were not disclosed.
Mitomics last month announced a realignment of its product development operations, resulting in the elimination of eight jobs. Earlier in the year, it signed a non-exclusive deal with LabMD to market the Prostate Core Mitomic Test in the US.